Checkpoint inhibitors in ovarian cancer: A review of preclinical data
Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with an improved response to chemotherapy and better...
Main Authors: | David W. Doo, Lyse A. Norian, Rebecca C. Arend |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-08-01
|
Series: | Gynecologic Oncology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235257891930058X |
Similar Items
-
A Review of the Role of Wnt in Cancer Immunomodulation
by: Whitney N. Goldsberry, et al.
Published: (2019-06-01) -
Re-Evaluating the Effects of Obesity on Cancer Immunotherapy Outcomes in Renal Cancer: What Do We Really Know?
by: Kristine I. Farag, et al.
Published: (2021-08-01) -
Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
by: Simona Duranti, et al.
Published: (2021-04-01) -
Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
by: Alice Indini, et al.
Published: (2021-04-01) -
The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer
by: Rachael M. Orlandella, et al.
Published: (2020-10-01)